Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Huntington Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44400   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    62 result(s) found for: Huntington Disease. Displaying page 2 of 4.
    « Previous 1  2  3  4  Next»
    EudraCT Number: 2013-001888-23 Sponsor Protocol Number: TV7820-CNS-20002 Start Date*: 2014-03-25
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc
    Full Title: A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus...
    Medical condition: Huntington’s disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) NL (Completed) AT (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-004556-15 Sponsor Protocol Number: WVE-003-001 Start Date*: 2021-03-12
    Sponsor Name:Wave Life Sciences UK Limited
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease
    Medical condition: Huntington's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) FR (Completed) DK (Completed) ES (Ongoing) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003637-42 Sponsor Protocol Number: WVE-HDSNP1-002 Start Date*: 2020-04-11
    Sponsor Name:Wave Life Sciences UK Limited
    Full Title: A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease
    Medical condition: Huntington's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011800-44 Sponsor Protocol Number: DIM20 Start Date*: 2009-10-07
    Sponsor Name:Medivation, Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease
    Medical condition: Huntington disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020469 Huntington's chorea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed) SE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003730-25 Sponsor Protocol Number: SBT20-102 Start Date*: 2017-02-14
    Sponsor Name:Stealth Bio Therapeutics Inc
    Full Title: A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington’s Disease.
    Medical condition: Huntington's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003898-94 Sponsor Protocol Number: BN40955 Start Date*: 2019-03-07
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON’S DISEASE
    Medical condition: Huntington's disease (HD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001131-23 Sponsor Protocol Number: S015-002 Start Date*: 2011-09-21
    Sponsor Name:Siena Biotech SpA
    Full Title: A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196
    Medical condition: Huntington's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000904-24 Sponsor Protocol Number: TV7820-CNS-20016 Start Date*: 2015-12-03
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc
    Full Title: A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease
    Medical condition: Huntington's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) AT (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023941-31 Sponsor Protocol Number: ETON Start Date*: 2011-05-20
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Effects of EGCG (Epigallocatechin Gallate) in Chorea Huntington
    Medical condition: Huntington´s Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001461-36 Sponsor Protocol Number: CT-AMT-130-02 Start Date*: 2021-06-30
    Sponsor Name:uniQure biopharma B.V.
    Full Title: A Phase Ib/II Randomised, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Ther...
    Medical condition: Huntington Disease
    Disease: Version SOC Term Classification Code Term Level
    27.1 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001991-32 Sponsor Protocol Number: BN42489 Start Date*: 2023-01-13
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, BIOMARKERS, AND EFFICACY OF TOMINERSEN IN INDIVIDUALS WITH PRODROMAL AND EARLY MANIFEST HUNTINGT...
    Medical condition: Huntington's disease (HD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) DE (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002822-10 Sponsor Protocol Number: PL101-HD301 Start Date*: 2020-12-11
    Sponsor Name:Prilenia Neurotherapeutics Ltd.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease
    Medical condition: Huntington Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) FR (Completed) CZ (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002987-14 Sponsor Protocol Number: BN40423 Start Date*: 2019-02-13
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST ...
    Medical condition: Huntington's disease (HD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) NL (Completed) AT (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-005142-39 Sponsor Protocol Number: WVE-HDSNP2-001 Start Date*: 2018-08-02
    Sponsor Name:Wave Life Sciences UK Limited
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease
    Medical condition: Huntington’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Prematurely Ended) FR (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-005095-10 Sponsor Protocol Number: WVE-HDSNP1-001 Start Date*: 2018-08-02
    Sponsor Name:Wave Life Sciences UK Limited
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease
    Medical condition: Huntington's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001314-19 Sponsor Protocol Number: VO659-CT01 Start Date*: 2023-04-25
    Sponsor Name:VICO Therapeutics B.V.
    Full Title: A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered VO659 in participants with sp...
    Medical condition: spinocerebellar ataxia types 1, 3 and Huntington’s disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 10010331 - Congenital, familial and genetic disorders 10057660 Spinocerebellar ataxia LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) IT (Prematurely Ended) DK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000418-75 Sponsor Protocol Number: TV5600-CNS-20007 Start Date*: 2014-11-18
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients...
    Medical condition: Huntington's Disease (HD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) CZ (Completed) DE (Completed) PT (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000394-60 Sponsor Protocol Number: ACR16C007 Start Date*: 2004-06-30
    Sponsor Name:A. Carlsson Research AB
    Full Title: A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease
    Medical condition: ACR16 belongs to a new class of CNS active agents called dopaminergic stabilizers. Dopaminergic stabilizers are compounds that can both enhance and counteract dopamine dependent functions in the CN...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015926-13 Sponsor Protocol Number: HD 01/09 Start Date*: 2010-03-03
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Treatment of Huntington´s disease with OSU 6162 - a pilot study
    Medical condition: Patients with Huntington´s disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004840-51 Sponsor Protocol Number: EIP19-NFD-401 Start Date*: 2019-06-26
    Sponsor Name:EIP Pharma, Inc.
    Full Title: A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD)
    Medical condition: Early-Stage Huntington Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 23 03:03:06 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA